Developments in the pharmacotherapeutic management of osteoporosis

Bibliography

• CUMMINGS SR, BLACK DM, RUBIN SM: Lifetime risks of hip, Colles’, or vertebral fracture and coronary heart disease among white postmenopausal women. Arch. Intern. Med. (1989) 149:2445-2448.
   PubMed Web of Science ®Google Scholar
• REGINSTER JY, ABADIE E, DELMAS P et al.: Recommendations for an update of the current (2001) regulatory requirements for registration of drugs to be used in the treatment of osteoporosis in postmenopausal women and in men. Osteoporos. Int. (2006) 17:1-7.
   Google Scholar
• LIBERMAN UA, WEISS SR, BROLL J et al.: Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N. Engl. J. Med. (1995) 333:1437-1443.
   PubMed Web of Science ®Google Scholar
• BLACK DM, CUMMINGS SR, KARPF DB et al.: Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet (1996) 348:1535-1541.
   PubMed Web of Science ®Google Scholar
• CUMMINGS SR, BLACK DM, THOMPSON DE et al.: Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures – results from the Fracture Intervention Trial. JAMA (1998) 280:2077-2082.
   PubMed Web of Science ®Google Scholar
• KARPF DB, SHAPIRO DR, SEEMAN E et al.: Prevention of nonvertebral fractures by alendronate. A meta-analysis. Alendronate Osteoporosis Treatment Study Groups. JAMA (1997) 277:1159-1164.
   PubMed Web of Science ®Google Scholar
• CRANNEY A, WELLS G, WILLAN A et al.: Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women. Endocr. Rev. (2002) 23:508-516.
   PubMed Web of Science ®Google Scholar
• BONE HG, HOSKING D, DEVOGELAER JP et al.: Ten years’ experience with alendronate for osteoporosis in postmenopausal women. N. Engl. J. Med. (2004) 350:1189-1199.
   PubMed Web of Science ®Google Scholar
• DE GROEN PC, LUBBE DF, HIRSCH LJ et al.: Esophagitis associated with the use of alendronate. N. Engl. J. Med. (1996) 335:1016-1021.
   PubMed Web of Science ®Google Scholar
• SCHNITZER T, BONE HG, CREPALDI G et al.: Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Aging (Milano) (2000) 12:1-12.
   PubMedGoogle Scholar
• HARRIS ST, WATTS NB, GENANT HK et al.: Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis. A randomized controlled trial. JAMA (1999) 282:1344-1352.
   PubMed Web of Science ®Google Scholar
• REGINSTER JY, MINNE HW, SORENSEN OH et al.: Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos. Int. (2000) 11:83-91.
   PubMed Web of Science ®Google Scholar
• WATTS NB, JOSSE RG, HAMDY RC et al.: Risedronate prevents new vertebral fractures in postmenopausal women at high risk. J. Clin. Endocrinol. Metab. (2003) 88:542-549.
   PubMed Web of Science ®Google Scholar
• SORENSEN OH, CRAWFORD GM, MULDER H et al.: Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience. Bone (2003) 32:120-126.
   PubMed Web of Science ®Google Scholar
• BOONEN S, MCCLUNG M, EASTELL R, FULEIHAN G, BARTON I, DELMAS P: Safety and efficacy of risedronate in reducing fracture risk in osteoporotic women 80 years of age or older: implications for the use of antiresorptive agents in the oldest old. J. Am. Geriatr. Soc. (2004) 52:1832-1839.
   PubMed Web of Science ®Google Scholar
• MCCLUNG MR, GEUSENS P, MILLER PD et al.: Hip Intervention Program Study Group: effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N. Engl. J. Med. (2001) 344:333-340.
   PubMed Web of Science ®Google Scholar
• CRANNEY A, TUGWELL P, ADACHI J et al.: Meta-analyses of therapies for postmenopausal osteoporosis. III. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis. Endocr. Rev. (2002) 23:517-523.
   PubMed Web of Science ®Google Scholar
• BROWN JP, KENDLER DL, MCCLUNG MR et al.: The efficacy and tolerability of risedronate once-a-week for the treatment of postmenopausal osteoporosis. Calcif. Tissue Int. (2002) 71:103-111.
   PubMed Web of Science ®Google Scholar
• CHESNUT CH, SKAG A, CHRISTIANSEN C et al.: Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J. Bone Miner. Res. (2004) 19:1241-1249.
   PubMed Web of Science ®Google Scholar
• REGINSTER JY, WILSON KM, DUMONT E, BONVOISIN B, BARRETT J: Monthly oral ibandronate is well tolerated and efficacious in postmenopausal women: results from the monthly oral pilot study. J. Clin. Endocrinol. Metab. (2005) 90:5018-5024.
   PubMed Web of Science ®Google Scholar
• REGINSTER JY, ADAMI S, LAKATOS P et al.: Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2-year results from the MOBILE study. Ann. Rheum. Dis. (2006) 65(5):654-661.
   PubMed Web of Science ®Google Scholar
• EMKEY R, KOLTUN W, BEUSTERIEN K et al.: Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, crossover trial: the Bonviva Alendronate trial in Osteoporosis (BALTO). Curr. Med. Res. Opin. (2005) 21:1895-1903.
   PubMed Web of Science ®Google Scholar
• REGINSTER JY, RABENDA V, NEUPREZ A: Adherence, patient preference and dosing frequency: understanding the relationship. Bone (2006) 38:S2-S6.
   PubMedGoogle Scholar
• REGINSTER JY: Oral and intravenous ibandronate in the management of postmenopausal osteoporosis: a comprehensive review. Curr. Pharm. Des. (2005) 11:3711-3728.
   PubMed Web of Science ®Google Scholar
• REID IR, BROWN JP, BURCKARDT P et al.: Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N. Engl. J. Med. (2002) 346:653-661.
   PubMed Web of Science ®Google Scholar
• POLASCIK TJ, GIVEN RW, METZGER C et al.: Open-label trial evaluating the safety and efficacy of zoledronic acid in preventing bone loss in patients with hormone-sensitive prostate cancer and bone metastases. Urology (2005) 66:1054-1059.
   PubMed Web of Science ®Google Scholar
• BAMIAS A, KASTRITIS E, BAMIA C et al.: Osteoporosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J. Clin. Oncol. (2005) 23:8580-8587.
   PubMed Web of Science ®Google Scholar
• MARX RE, SAWATARI Y, FORTIN M, BROUMAND V: Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J. Oral Maxillofac. Surg. (2005) 63:1567-1575.
   PubMed Web of Science ®Google Scholar
• RIGGS BL, HARTMANN LC: Selective estrogen-receptor modulators – mechanisms of action and application to clinical practice. N. Engl. J. Med. (2003) 348:618-629.
   PubMed Web of Science ®Google Scholar
• EARLY BREAST CANCER TRIALISTS’ COLLABORATIVE GROUP: Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet (1998) 351:1451-1467.
   PubMed Web of Science ®Google Scholar
• RYAN WG, WOLTER J, BAGDADE JD: Apparent beneficial effect of tamoxifen on bone mineral content in patients with breast cancer: preliminary study. Osteoporos. Int. (1991) 2:39-41.
   PubMed Web of Science ®Google Scholar
• ETTINGER B, BLACK DM, MITLAK BH et al.: Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA (1999) 282:637-645.
   PubMed Web of Science ®Google Scholar
• MARICIC M, ADACHI JD, SARKAR S, WU W, WONG M, HARPER KD: Early effects of raloxifene on clinical vertebral fractures at 12 months in postmenopausal women with osteoporosis. Arch. Intern. Med. (2002) 162:1140-1143.
   PubMed Web of Science ®Google Scholar
• DELMAS PD, GENANT HK, CRANS GG et al.: Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial. Bone (2003) 33:522-532.
   PubMed Web of Science ®Google Scholar
• SIRIS E, ADACHI JD, LU Y et al.: Effects of raloxifene on fracture severity in postmenopausal women with osteoporosis: results from the MORE study. Osteoporos. Int. (2002) 13:907-913.
   PubMed Web of Science ®Google Scholar
• KANIS JA, JOHNELL O, BLACK DM et al.: Effect of raloxifene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis: a reanalysis of the Multiple Outcomes of Raloxifene Evaluation trial. Bone (2003) 33:293-300.
   PubMed Web of Science ®Google Scholar
• DELMAS PD, ENSRUD KE, ADACHI JD et al.: Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J. Clin. Endocrinol. Metab. (2002) 87:3609-3617.
   PubMed Web of Science ®Google Scholar
• CUMMINGS SR, ECKERT S, KRUEGER KA et al.: The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA (1999) 281:2189-2197.
   PubMed Web of Science ®Google Scholar
• MARTINO S, CAULEY JA, BARRETT-CONNOR E et al.: Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J. Natl. Cancer Inst. (2004) 96:1751-1761.
   PubMed Web of Science ®Google Scholar
• REGINSTER JY, DEVOGELAER JP: Raloxifene reduces fractures in postmenopausal women with osteoporosis. Clin. Orthop. Rel. Res. (2006) 443:48-54.
   PubMedGoogle Scholar
• KE HZ, FOLEY GL, SIMMONS HA, SHEN V, THOMPSON DD: Long-term treatment of lasofoxifene preserves bone mass and bone strength and does not adversely affect the uterus in ovariectomized rats. Endocrinology (2004) 145(4):1996-2005.
   PubMed Web of Science ®Google Scholar
• Lasofoxifene: CP 336156, CP-336156. Drugs R D (2005) 6(1):56-60.
   PubMedGoogle Scholar
• SARKAR S, MITLAK BH, WONG M, STOCK JL, BLACK DM, HARPER KD: Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy. J. Bone Miner. Res. (2002) 17:1-10.
   PubMed Web of Science ®Google Scholar
• GENNARI L: Lasofoxifene (Pfizer). Curr. Opin. Investig. Drugs (2005) 6:1067-1078.
   PubMedGoogle Scholar
• KOMM BS, KHARODE YP, BODINE PV, HARRIS HA, MILLER CP, LYTTLE CR: Bazedoxifene acetate: a selective estrogen receptor modulator with improved selectivity. Endocrinology (2005) 146:3999-4008.
   PubMed Web of Science ®Google Scholar
• GRUBER C, GRUBER D: Bazedoxifene (Wyeth). Curr. Opin. Investig. Drugs (2004) 5(10):1086-1093.
   PubMedGoogle Scholar
• SATO M, TURNER CH, WANG T, ANDRIAN MD, ROWLEY E, BRYANT HU: LY35338LIICI: a novel raloxifene analog with improved SERM potency and efficacy in vivo. Pharmacol. Exp. Ther. (1998) 287:1-7.
   PubMed Web of Science ®Google Scholar
• MA YL, BRYANT HU, ZENG Q et al.: Long-term dosing of arzoxifene lowers cholesterol, reduces bone turnover, and preserves bone quality in ovariectomized rats. J. Bone Miner. Res. (2002) 17:2256-2264.
   PubMed Web of Science ®Google Scholar
• REGINSTER JY, TAQUET AN, FRAIKIN G, GOSSET C, ZEGELS B: Parathyroid hormone in the treatment of involutional osteoporosis: back to the future. Osteoporos. Int. (1997) 7:S163-S167.
   Web of Science ®Google Scholar
• NEER RM, ARNAUD CD, ZANCHETTA JR et al.: Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N. Engl. J. Med. (2001) 344:1434-1441.
   PubMed Web of Science ®Google Scholar
• MARCUS R, WANG O, SATTERWHITE J, MITLAK B: The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis. J. Bone Miner. Res. (2003) 18:18-23.
   PubMed Web of Science ®Google Scholar
• LINDSAY R, SCHEELS WH, NEER R et al.: Sustained vertebral fracture risk reduction after withdrawal of teriparatide (recombinant human parathyroid hormone (1-34)) in postmenopausal women with osteoporosis. Arch. Int. Med. (2004) 164:2024-2030.
   PubMed Web of Science ®Google Scholar
• PRINCE R, SIPOS A, HOSSAIN A et al.: Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment. J. Bone Miner. Res. (2005) 20:1507-1513.
   PubMed Web of Science ®Google Scholar
• BLACK DM, GREENSPAN SL, ENSRUD KE et al.: The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N. Engl. J. Med. (2003) 349:1207-1215.
   PubMed Web of Science ®Google Scholar
• KHOLSA S: Parathyroid hormone plus alendronate – a combination that does not add up. N. Engl. J. Med. (2003) 349:1277-1279.
   PubMed Web of Science ®Google Scholar
• RABENDA V, HANSSENS L, DE CEULAER F, REGINSTER JY: Is there any interest in combining treatments in osteoporosis? Curr. Rheum. Reviews (2005) 1:49-55.
   Google Scholar
• JILKA RL, WEINSTEIN RS, BELLIDO T, ROBERSON P, PARFITT AM, MANOLAGAS SC: Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J. Clin. Invest. (1999) 104:371-373.
   PubMed Web of Science ®Google Scholar
• SHRADER SP, RAGGUCCI KR: Parathyroid hormone (1-84) and treatment of osteoporosis. Ann. Pharmacother. (2005) 39:1511-1516.
   PubMed Web of Science ®Google Scholar
• HODSMAN AB, HANLEY DA, ETTINGER MP et al.: Efficacy and safety of human parathyroid hormone (1-84) in increasing bone mineral density in postmenopausal osteoporosis. J. Clin. Endocrinol. Metab. (2003) 88:5212-5220.
   PubMed Web of Science ®Google Scholar
• HODSMAN AB, BAUER DC, DEMPSTER DW et al.: Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr. Rev. (2005) 26:688-703.
   PubMed Web of Science ®Google Scholar
• MEUNIER PJ, SLOSMAN D, DELMAS P et al.: Strontium ranelate: dose-dependent effects in established postmenopausal vertebral osteoporosis: a 2-year randomized placebo controlled trial. J. Clin. Endocrinol. Metab. (2002) 87:2060-2066.
   PubMed Web of Science ®Google Scholar
• REGINSTER JY, SPECTOR T, BADURSKI J et al.: A short-term run-in study can significantly contribute to increasing the quality of long-term osteoporosis trials. The Strontium Ranelate Phase III Program. Osteoporos. Int. (2002) 13(S1):S30.
   Google Scholar
• MEUNIER PJ, ROUX C, SEEMAN E et al.: The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N. Engl. J. Med. (2004) 350:459-468.
   PubMed Web of Science ®Google Scholar
• REGINSTER JY, SEEMAN E, DE VERNEJOUL MC et al.: Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J. Clin. Endocrinol. Metab. (2005) 90:2816-2822.
   PubMed Web of Science ®Google Scholar
• HOFBAUER LC, SCHOPPET M: Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular disease. JAMA (2004) 292:490-495.
   PubMed Web of Science ®Google Scholar
• ABDALLAH BM, STILGREN LS, NISSEN N, KASSEM M, JORGENSEN HR, ABRAHAMSEN B: Increased RANKL/OPG mRNA ratio in iliac bone biopsies from women with hip fractures. Calcif. Tissue Int. (2005) 76:90-97.
   PubMed Web of Science ®Google Scholar
• BEKKER PJ, HOLLOWAY DL, RASMUSSEN AS et al.: A single-dose placebo-controlled study of MAG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J. Bone Miner. Res. (2004) 19:1059-1066.
   PubMed Web of Science ®Google Scholar
• MCCLUNG MR, LEWIECKI EM, COHEN SB et al.: Denosumab in postmenopausal women with low bone mineral density. N. Engl. J. Med. (2006) 354:821-831.
   PubMed Web of Science ®Google Scholar
• YASUDA Y, KALETA J, BROMME D: The role of cathepsins in osteoporosis and arthritis: rationale for the design of new therapeutics. Adv. Drug Deliv. Rev. (2005) 57:973-993.
   PubMed Web of Science ®Google Scholar
• GRABOWSKAL U, CHAMBERS TJ, SHIROO M: Recent developments in cathepsin K inhibitor design. Curr. Opin. Drug Discov. Devel. (2005) 8:619-630.
   PubMed Web of Science ®Google Scholar
• BISKOBING DM: Novel therapies of osteoporosis. Expert Opin. Investig. Drugs (2003) 12(4):611-621.
   PubMed Web of Science ®Google Scholar
• LARK MW, STROUP GB, JAMES IE et al.: A potent small molecule, nonpeptide inhibitor of cathepsin K (SB 331750) prevents bone matrix resorption in the ovariectomized rat. Bone (2002) 30:746-753.
   PubMed Web of Science ®Google Scholar
• STROUP GB, LARK MW, VEBER DF et al.: Potent and selective inhibition of human cathepsin K leads to inhibition of bone resorption in vivo nonhuman primate. J. Bone Miner. Res. (2001) 16:1739-1746.
   PubMed Web of Science ®Google Scholar
• BOONEN S, BODY JJ, BOUTSEN Y et al.: Evidence-based guidelines for the treatment of postmenopausal osteoporosis: a consensus document of the Belgian Bone Club. Osteoporos. Int. (2005) 16:239-254.
   PubMed Web of Science ®Google Scholar